Overexpression of HK2 predicts poor prognosis in human non-small cell lung cancer 23-25, breast cancer 26, and hepatocellular carcinoma 27.Previous studies have demonstrated that GBM cells prefer to acquire energy from glycolysis instead of oxidative phosphorylation, and suppression of glycolysis is proposed to be a promising treatment option for human GBM 28-30. Here, HK2 is linked to glioblastoma.